Bio-Rad Laboratories BIO recently announced the launch of four new Droplet Digital PCR (ddPCR) platforms. The newly introduced instruments include the company's QX Continuum ddPCR system, along with ...

Bio-Rad Laboratories, Inc.’s BIO solid momentum in the QX600 Droplet Digital PCR (ddPCR) platform is poised to help it grow in the upcoming quarters. The clinical diagnostics business sees ...

Image Source: Zacks Investment Research Digital PCR Business Backs Bio-Rad’s Growth: Bio-Rad’s QX600 ddPCR platform is currently robust and continues to expand.

Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of four new Droplet Digital™ PCR (ddPCR™) platforms ...

We believe that Oncocyte’s transplant monitoring assays and the Bio-Rad QX600 ddPCR System solution for the noninvasive measurement and quantification of key biomarkers used in solid tissue ...

The pipeline of Bio-Rad’s QX600 Droplet Digital PCR (ddPCR) platform is currently robust and growing. Backed by the tremendous customer response, the company continues to ramp up production ...

Bio-Rad’s QX600™ Droplet Digital PCR System offers unmatched sensitivity, precision, and absolute quantification capabilities, and can be used by researchers to detect disease markers such as ...

Simon May, executive vice president and president, life sciences, Bio-Rad, commented: “We believe that Oncocyte’s transplant monitoring assays and the Bio-Rad QX600 ddPCR system solution for the ...

Combined with Bio-Rad’s existing line of QX200 and QX600 ddPCR systems, the expanded product portfolio — now including more than 400,000 assays — offers the most comprehensive line of ...

Under the terms of the agreement, Bio-Rad has committed to participate in a private placement of Oncocyte’s equity and has secured exclusive commercial rights in certain markets to commercialize ...